样式: 排序: IF: - GO 导出 标记为已读
-
Acute rejection post lung transplant. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-04-25 Justin Hanks, Christine Girard, Sameep Sehgal
To review what is currently known about the pathogenesis, diagnosis, treatment, and prevention of acute rejection (AR) in lung transplantation.
-
Improving care in lung cancer surgery: a review of quality measures and evolving standards. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-04-09 Rachel M Lee, Ravi Rajaram
Lung cancer is the leading cause of cancer-related death in the United States. Pulmonary resection, in addition to perioperative systemic therapies, is a cornerstone of treatment for operable patients with early-stage and locoregional disease. In recent years, increased emphasis has been placed on surgical quality metrics: specific and evidence-based structural, process, and outcome measures that aim
-
How do we expand the lung donor pool? Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-03-29 Bronwyn J Levvey, Gregory I Snell
Lung transplantation activity continues to be limited by the availability of timely quality donor lungs. It is apparent though that progress has been made. The steady evolution of clinical practice, combined with painstaking scientific discovery and innovation are described.
-
An update of palliative care in lung transplantation with a focus on symptoms, quality of life and functional outcomes. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-03-28 Dmitry Rozenberg, Rogih Riad Andrawes, Kirsten Wentlandt
Palliative care (PC) in lung transplantation is increasingly acknowledged for its important role in addressing symptoms, enhancing functionality, and facilitating advance care planning for patients, families, and caregivers. The present review provides an update in PC management in lung transplantation.
-
Asthma in pregnancy: a review of recent literature. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-03-14 Kelly Colas, Jennifer Namazy
Asthma remains the most common respiratory disease in pregnancy. Identifying risk factors for asthma exacerbations during pregnancy is critical, as uncontrolled asthma can have detrimental effects for both mother and baby. In this review, we discuss recent literature exploring risk factors, fetal and maternal effects, and treatment options for asthma during pregnancy.
-
Obesity-related asthma: new insights leading to a different approach. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-03-05 Adjan Witte, Yasemin Türk, Gert-Jan Braunstahl
Obesity is a growing global health threat that significantly contributes to the burden of asthma by increasing the risk of developing asthma and exerting a distinct effect on lung function and inflammation. The treatment of obesity-related asthma is hindered by a poor response to standard asthma treatments, leading to worse asthma control. Weight loss strategies have a significant effect on asthma
-
Long-term safety, durability of response, cessation and switching of biologics. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-03-04 Arjun Mohan, Anna Y Qiu, Njira Lugogo
Severe asthma patients suffer from decreased quality of life, and increased asthma symptoms, exacerbations, hospitalizations, and risk of death. Biologics have revolutionized treatment for severe asthma. However, with multiple biologic agents now available, clinicians must consider initial selection the long-term effectiveness of biologics. Additionally, patients have overlapping eligibilities and
-
Remission in asthma. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-29 Marek Lommatzsch
To review the current concepts of remission in asthma.
-
Recent developments in occupational asthma. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-29 Claudia Blouin, Catherine Lemière
Occupational asthma (OA) is a complex condition that can be difficult to diagnose. The purpose of this review is to describe some recent findings regarding the epidemiology of OA, the occupational sensitizing agents, the prognosis of OA, and its primary prevention.
-
Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-27 Pedro A Lamothe, Violeta Capric, F Eun-Hyung Lee
Asthma exacerbations are associated with substantial symptom burden and healthcare costs. Viral infections are the most common identified cause of asthma exacerbations. The epidemiology of viral respiratory infections has undergone a significant evolution during the COVID-19 pandemic. The relationship between viruses and asthmatic hosts has long been recognized but it is still incompletely understood
-
Examining the impact of air pollution, climate change, and social determinants of health on asthma and environmental justice. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-27 Felicia T Canaday, Steve N Georas, Daniel P Croft
In this review, we discuss the current literature examining the impact air pollution and climate change has on asthma onset, control, and exacerbation. This review also addresses the risk of exposure to specific disproportionately affected communities, highlighting health disparities in exposure and asthma outcomes.
-
Lobar or sublobar resection of peripheral stage I non-small cell lung cancer. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-27 Pedro Guimarães Rocha Lima, Matthieu Glorion, Moishe Liberman
We aim to highlight two recent clinical trials that have altered the approach of the management of stage I nonsmall cell lung cancer.
-
The changing landscape of infections in the lung transplant recipient. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-27 Jessica Lum, Christine Koval
Infections in lung transplant recipients remain a major challenge and can affect lung allograft function and cause significant morbidity and mortality. New strategies for the prevention and treatment of infection in lung transplantation have emerged and are reviewed.
-
Disparities across the continuum of lung cancer care: a review of recent literature. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-26 Lauren Kearney, Tatyana Nguyen, Katrina Steiling
Lung cancer remains the leading cause of cancer mortality worldwide. Health disparities have long been noted in lung cancer incidence and survival and persist across the continuum of care. Understanding the gaps in care that arise from disparities in lung cancer risk, screening, treatment, and survivorship are essential to guiding efforts to achieve equitable care.
-
Digital inhalers for asthma management. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-22 Giselle Mosnaim, Melinda Rathkopf
Although digital inhaler systems for asthma management have been commercially available for over a decade, their current use in clinical practice is limited. This review outlines barriers and offers potential solutions to their implementation.
-
Lung abscess: an update on the current knowledge and call for future investigations. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-20 Søren Sperling, Victor Naestholt Dahl, Andreas Fløe
Lung abscess is a severe and complex respiratory infection. The purpose of this review is to discuss recent publications on lung abscess, covering topics such as epidemiology, clinical presentation, diagnosis, and treatment and prevention.
-
Lung infections due to emerging fungal pathogens. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-16 Francisco J Machiavello Roman, Lauren Pischel, Marwan M Azar
This review highlights the epidemiology, pathogenesis and clinical management of pulmonary infections caused by emerging fungal organisms.
-
The role of oscillometry in asthma. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-16 Patrick A Donohue, David A Kaminsky
Oscillometry is a noninvasive pulmonary function test that has gained significant interest in the evaluation of lung disease. Currently, oscillometry is primarily a research tool, but there is a growing body of evidence supporting its clinical use. This review describes the recent work evaluating the role of oscillometry in the diagnosis and treatment of asthma.
-
Bacteriophages for bronchiectasis: treatment of the future? Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-13 Catherine Dominic, Hannah V Pye, Eleanor K Mishra, Evelien M Adriaenssens
Bronchiectasis is a chronic respiratory disease characterized by dilated airways, persistent sputum production and recurrent infective exacerbations. The microbiology of bronchiectasis includes various potentially pathogenic microorganisms including Pseudomonas aeruginosa which is commonly cultured from patients' sputum. P. aeruginosa is difficult to eradicate and frequently exhibits antimicrobial
-
Thoracic empyema: aetiology, diagnosis, treatment, and prevention. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-08 Na'im Merchant, Chantal Liu
The aim of this study was to review current key points in the aetiology, diagnosis, treatment, and prevention of empyema thoracis. Early postpandemic trends have seen an increasing global incidence and evolution in the aetiology of empyema. Due to varied aetiology and typically lengthy treatment, empyema will be disproportionately affected by the rising tide of antimicrobial resistance (AMR), thus
-
Pulmonary infections in the returning traveler. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-07 Francesca F Norman, Marta Gonzalez-Sanz
The recent COVID-19 pandemic has shaped the epidemiology of other infectious diseases globally. International tourist arrivals are increasing and recovering to prepandemic levels. This review focuses on respiratory infections in travelers, highlighting the characteristics of the main imported viral, bacterial, fungal, and parasitic infections with pulmonary involvement.
-
Tuberculous pleuritis: clinical presentations and diagnostic challenges. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-07 Ken Ka Pang Chan, Yun Chor Gary Lee
Tuberculous pleuritis (TBP) is one of the most common types of extrapulmonary tuberculosis. We highlight the latest epidemiology of TBP, the heterogeneity of its presentation and the performance of different diagnostic strategies.
-
Artificial intelligence for the optimal management of community-acquired pneumonia. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-03 Maria Antonietta Barbieri, Vera Battini, Sessa Maurizio
This timely review explores the integration of artificial intelligence (AI) into community-acquired pneumonia (CAP) management, emphasizing its relevance in predicting the risk of hospitalization. With CAP remaining a global public health concern, the review highlights the need for efficient and reliable AI tools to optimize resource allocation and improve patient outcomes.
-
The diagnosis and management of chronic lung allograft dysfunction. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-02-03 Geert M Verleden, Jeroen M H Hendriks, Stijn E Verleden
Chronic lung allograft dysfunction (CLAD) remains a life-threatening complication following lung transplantation. Different CLAD phenotypes have recently been defined, based on the combination of pulmonary function testing and chest computed tomography (CT) scanning and spurred renewed interests in differential diagnosis, risk factors and management of CLAD.
-
The role of chest computed tomography in the evaluation and management of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-01-17 Robert M Burkes, Muhammad A Zafar, Ralph J Panos
The purpose of this review is to compile recent data on the clinical associations of computed tomography (CT) scan findings in the literature and potential avenues for implementation into clinical practice.
-
Training in interventional pulmonology: a leap into the future. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2024-01-11 Carla Lamb, Ash Sachdeva
This review holds significant relevance and is timely; as of June 2022, the United States Accreditation Council of Graduate Medical Education (ACGME) formally recognized interventional pulmonary medicine as a novel subspecialty with a unique fellowship training program pathway beyond Pulmonary and Critical Care Medicine. This recognition stands as a culmination of extensive efforts spanning decades
-
Selected updates on chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-12-18 Jordina Mah, Andrew I Ritchie, Lydia J Finney
Chronic obstructive pulmonary disease (COPD) is preventable disease and yet it remains the third greatest cause of death worldwide. This review focuses on recent updates in COPD research which have had an impact on our understanding of the epidemiology and pathophysiology of COPD.
-
Pulmonary hypertension in chronic obstructive pulmonary disease: current understanding, knowledge gaps and future directions. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-12-14 William T Atchley, Teja Krishna Kakkera
Despite the advent of effective and mechanistically diverse treatments for pulmonary arterial hypertension (PAH) and their positive impacts on the functional capacities and outcomes for PAH patients, the much larger population of patients with pulmonary hypertension (PH) in chronic lung diseases like chronic obstructive pulmonary disease (PH-COPD) remain without effective therapies.
-
Chronic obstructive pulmonary disease and cardiovascular disease: mechanistic links and implications for practice. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-12-13 Tetsuro Maeda, Mark T Dransfield
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are both significant burdens on the healthcare system and often coexist. Mechanistic links between the two conditions and their clinical impact are increasingly understood.
-
Medical thoracoscopy for pleural diseases. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-14 Matsuo So, Udit Chaddha, Samira Shojaee, Pyng Lee
The purpose of this review is to elaborate on the role of medical thoracoscopy for various diagnostic and therapeutic parietal pleural interventions. The renewed interest in medical thoracoscopy has been boosted by the growth of the field of interventional pulmonology and, possibly, well tolerated and evolving anesthesia.
-
Bronchoscopic interventions for chronic bronchitis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-10 Anand Tana, Chenchen Zhang, David DiBardino, Christopher M Orton, Pallav L Shah
Chronic bronchitis is a phenotype of chronic obstructive pulmonary disease (COPD), characterized by chronic cough and sputum production, associated with an increased rate of COPD exacerbations and hospital admissions, a more rapid decline in lung function and reduced life expectancy. Despite optimal medical therapy, chronic bronchitis remains difficult to treat. Interventional bronchoscopic procedures
-
Practical challenges in lung cancer pathology: bedside care to treatment decisions. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-09 Angela Maria Takano, Chun Yuen Chow, Kiat Hon Lim
Lung cancer is one of the most common malignancies in the whole world, and the pulmonologist is generally the first medical professional to meet the patient and decide what method of tumour sampling is preferable in each specific case. It is imperative for pulmonary physicians to be aware of the intricacies of the diagnostic process, and understand the multiple challenges that are encountered, from
-
Advancements in airway stents: a comprehensive update. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-09 Carlos Aravena, Thomas R Gildea
This review provides an overview of the evolving field of airway stenting (AS), highlighting its relevance in the management of central airway obstruction (CAO). It discusses recent advancements, including 3D-printed silicone stents (3DPSS), metallic stents, biodegradable stents (BS), and drug-eluting stents (DES), which are transforming clinical practice. The review underscores the ongoing challenges
-
Tobacco treatment in the setting of lung cancer screening. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-08 James E Verdone,Ellen T Marciniak,Janaki Deepak
PURPOSE OF REVIEW Lung cancer screening by low-dose CT is an increasingly implemented preventive medicine tool. Screening for lung cancer is incomplete without addressing problematic tobacco use, the greatest modifiable risk factor in the development of lung cancer. This review describes recent work related to lung cancer screening and treatment of tobacco use in that context. RECENT FINDINGS Implementation
-
Pediatric interventional bronchoscopy: from early limitations to achievable opportunities. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-08 Megan N Januska,Kimberley Kaspy,Kubra M Bozkanat,Alfin G Vicencio
PURPOSE OF REVIEW The rapid evolution of bronchoscopy equipment and technologies, from the introduction of the 1.1 mm flexible cryoprobe to the use of navigational and robotic bronchoscopy, has afforded unprecedented opportunities for pediatric advanced diagnostic and interventional bronchoscopy. While there is growing interest among pediatric pulmonologists to incorporate these new techniques into
-
Advances in navigating to the nodule and targeting. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-11-07 Jeffrey Graham,Madeleine Basist,Laura Frye,Abhinav Agrawal,Faria Nasim
PURPOSE OF REVIEW The multitude of available platforms and imaging modalities for navigational bronchoscopy, in combination with the various sampling tools that can be used intra-procedurally, is complex. This review seeks to describe the recent developments in peripheral bronchoscopy in regards to navigation, imaging, and sampling target lesions in the pulmonary parenchyma. RECENT FINDINGS Robotic
-
Burden, clinical features, and outcomes of post-tuberculosis chronic obstructive lung diseases. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-10-31 Inderpaul Singh Sehgal,Sahajal Dhooria,Valliappan Muthu,Helmut J F Salzer,Ritesh Agarwal
PURPOSE OF REVIEW Post-tuberculosis lung disease (PTLD) is an increasingly recognized and debilitating consequence of pulmonary tuberculosis (PTB). In this review, we provide a comprehensive overview of PTLD with airflow obstruction (PTLD-AFO), focusing on its burden, pathophysiology, clinical manifestations, diagnostic methods, and management strategies. RECENT FINDINGS The relationship between PTLD
-
Supplemental oxygen therapy in chronic obstructive pulmonary disease: is less is more? How much is too much? Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-10-27 Ayham Daher, Michael Dreher
Currently available evidence supporting the use of supplemental oxygen therapy (SOT) in chronic obstructive pulmonary disease (COPD) is complex, and data on the mortality reduction associated with SOT usage in patients with severe daytime resting hypoxemia have not been updated since the development of other treatments.
-
Mild airways obstruction: spirometric diagnostic pitfalls and solutions. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-10-19 Nawaf M Alotaibi, Rachel L Eddy, Don D Sin
Spirometry is a validated tool in the diagnosis of obstructive airways disease. However, it may be insufficiently sensitive in detecting airflow limitation in the small airways. This review highlights common clinical scenarios wherein airflow limitation may be missed or overlooked.
-
What is new in mediastinal staging? Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-10-19 Audra J Schwalk, Abesh Niroula, Matthew Schimmel
Appropriate staging is of utmost importance in nonsmall cell lung cancer (NSCLC), as the pathologic stage dictates both overall prognosis and appropriate therapeutic pathways. This article seeks to review the current recommendations for mediastinal staging of NSCLC and available modalities to achieve this. Landmark publications pertaining to recent advancements in NSCLC treatments are also highlighted
-
Towards treatments for silicosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-10-19 Hayley Barnes, Maggie Lam, Michelle D Tate, Ryan Hoy
There has been a rapid increase in silicosis cases, particularly related to artificial stone. The key to management is avoidance of silica exposure. Despite this, many develop progressive disease and there are no routinely recommended treatments. This review provides a summary of the literature pertaining to pharmacological therapies for silicosis and examines the plausibility of success of such treatments
-
Prader-Willi syndrome: an update. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-13 Jessica Duis
Sleep disorders in Prader-Willi syndrome (PWS) range from respiratory to neurological disorders of sleep. We now recognize the role of excessive daytime sleepiness (present in the infant period and throughout life), and a modified narcolepsy phenotype with or without cataplexy. Disordered sleep in PWS may present with symptoms pervasive to daily function, including inattention at school, irritability
-
Genetic therapies in cystic fibrosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-13 Jennifer L Taylor-Cousar, A Christopher Boyd, Eric W F W Alton, Deepika Polineni
Advances in cystic fibrosis (CF) therapies over the past decade pivotally changed the morbidity and mortality of CF with the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators that rescue dysfunctional CFTR protein in individuals with eligible genotypes. However, a significant proportion of the CF population is in need of alternative treatment strategies to address CFTR
-
Evolving nutritional needs, obesity, and overweight status in cystic fibrosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-12 Sylvia E Szentpetery
The nutritional landscape in cystic fibrosis has shifted dramatically in the era of CFTR modulator therapy. In this review, we will critically examine the literature on overweight and obesity in CF, current nutritional care unknowns and opportunities for further investigation or adaptation in clinical care.
-
Obstructive sleep apnea in the patient with atrial fibrillation: current knowledge and remaining uncertainties. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-11 Owen D Lyons
Obstructive sleep apnea (OSA) is highly prevalent in patients with atrial fibrillation and plays a causal role for OSA in the pathogenesis of atrial fibrillation. The presence of OSA in atrial fibrillation is associated with increased symptom burden and increased risk of hospitalizations. Furthermore, untreated OSA is associated with an increased risk of atrial fibrillation recurrence post ablation
-
Cystic fibrosis liver disease in the post-modulator era. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-06 Michael R Narkewicz
Highly effective modulators of cystic fibrosis transmembrane conductance regulator (CFTR) function have had dramatic impact on pulmonary and nutritional outcomes in persons with cystic fibrosis (pwCF). The impact on liver disease in pwCF was not the focus of the registration trials. The purpose of this review is to assess the current literature on the impact of HEMT on liver disease, progression, regression
-
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-04 Michael B VanElzakker, Emma M Tillman, Lael Yonker, Eva-Maria Ratai, Anna M Georgiopoulos
This review highlights the problem of neuropsychiatric adverse effects (AEs) associated with elexacaftor/tezacaftor/ivacaftor (ETI), current suboptimal mitigation approaches, a novel testable mechanistic hypothesis, and potential solutions requiring further research.
-
Casting light on the many facets of sarcoidosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-01 Rémy L M Mostard,Anne-Marie Russell
-
Update on the genetic basis of obstructive sleep apnoea - hype or hope? Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-01 Renata L Riha
The obstructive sleep apnoea syndrome (OSAS) is a chronic, common condition in western societies which can lead to adverse cardiometabolic effects if left untreated and is one of the commonest causes of excessive daytime somnolence.
-
The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-09-01 Raksha Jain, Traci M Kazmerski, Jennifer L Taylor-Cousar
With improved long-term survival and the expanding availability of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies that treat the underlying genetic defect in cystic fibrosis, more people are interested in parenthood. Cystic fibrosis care centers and people with cystic fibrosis need more information to guide decisions related to parenting.
-
Perioperative management of Obstructive Sleep Apnoea: Present themes and future directions. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-31 Tom Chambers, Harry Bamber, Nanak Singh
Obstructive sleep apnoea (OSA) is an increasingly common pathology that all those involved in perioperative care will come across. Patients with the condition present a challenge at many stages along the perioperative journey, not least because many patients living with OSA are unaware of their diagnosis.Key interventions can be made pre, intra-, and postoperatively to improve outcomes. Knowledge of
-
Co-morbid insomnia and sleep apnea (COMISA): recent research and future directions. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-30 Alexander Sweetman, Amal Osman, Leon Lack, Megan Crawford, Douglas Wallace
Insomnia and obstructive sleep apnea have previously been viewed as completely independent conditions. However, there is now increasing recognition that insomnia and sleep apnea frequently co-occur. Co-morbid insomnia and sleep apnea (COMISA) is a highly prevalent condition that is associated with impairment of sleep, daytime function, mental health and physical health outcomes, and mortality risk
-
Breath of fresh insight: unraveling the evolution of our understanding of cystic fibrosis pulmonary exacerbations. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-30 Ranjani Somayaji, Bradley S Quon
Pulmonary exacerbations are critical events with significant negative impacts in persons with cystic fibrosis, but their diagnosis and management are highly variable. Highly effective modulator therapies have greatly improved health and reduced exacerbation events, but have also reshaped how they present. This review discusses the complexities of the diagnosis and management of pulmonary exacerbations
-
Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-24 Katherine E Wajda, Erica A Roesch, Alex H Gifford
Cystic fibrosis is a genetic disease that increases risk of death from respiratory failure because of impairment in mucociliary clearance. Complex daily care regimens including medications and airway clearance techniques (ACTs) aim to preserve lung function and alleviate symptoms for people with cystic fibrosis (pwCF). The success of highly effective modulator therapy (HEMT) permits evaluation of treatment
-
Health inequities in the modulator era. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-24 John B Palla, Theresa A Laguna
To discuss the existing health inequities in people with cystic fibrosis (CF) and how the recent development of cystic fibrosis transmembrane regulator (CFTR) modulators may impact these inequities.
-
Mechanisms relating to sleeping position to the endotypes of sleep disordered breathing. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-17 Ludovico Messineo,Simon Joosten,Elisa Perger
PURPOSE Obstructive sleep apnea (OSA) severity varies considerably depending on the body position during sleep in certain subjects. Such variability may be underpinned by specific, body position-related changes in OSA pathophysiological determinants, or endotypes. Also head position relative to trunk may influence OSA endotypes. However, no studies to our knowledge have reviewed the endotype variations
-
The controversy over daylight saving time: evidence for and against. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-08-13 Michael C Antle
PURPOSE OF REVIEW Biannual clock changes to and from daylight saving time have been pervasive in many societies for over 50 years. Governments are considering abandoning this practice and choosing a single permanent time. RECENT FINDINGS Our endogenous circadian clock follows our photoperiod, which changes over the year. The acute disruption caused by changing our clocks can affect safety (motor vehicle
-
Sarcoidosis and frailty: recognizing factors that foster holistic resilience. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-07-31 Lesley Ann Saketkoo, Anne-Marie Russell, Karen C Patterson, Ogugua Ndili Obi, Marjolein Drent
Sarcoidosis is a multiorgan system disease exerting significant impact on biophysical, social, psychological and emotional well-being. Mortality and disability correlate to accessible, timely, expert care for sarcoidosis and its related complications. Across health conditions, positive healthcare interactions and interventions can rehabilitate unfavourable factors tied to concepts of 'frailty'. Here
-
Updates in the diagnosis and management of chronic thromboembolic disease. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-07-18 Alisha Kabadi, Kim Kerr, Timothy M Fernandes
Chronic thromboembolic disease (CTED) is distinct from chronic thromboembolic pulmonary hypertension (CTEPH) and is defined by dyspnea on exertion after acute pulmonary embolism with the presence of residual perfusion defects and absence of resting pulmonary hypertension. Here, we review clinical features and diagnostic criteria for CTED and summarize treatment options.
-
Organ involvement and assessment in sarcoidosis. Curr. Opin. Pulm. Med. (IF 3.3) Pub Date : 2023-07-18 Marlou T H F Janssen, Robert B M Landewé, Marco C Post, Roel J Erckens, Rémy L M Mostard
In recent years new recommendations have been published about organ assessment in the diagnosis of sarcoidosis.